“Large investments are too often made in studies
that provide poor-quality evidence,1 are
overtly biased,2 are
not applicable to most patients,3 or
yield results that do not address the real concerns of individuals facing
clinical decisions.4,5”
[1]
(Patient Centered Outcomes Research Center, JAMA,
April 18, 2012)
Indeed. This is not only “too often”, it is in fact
characteristic of most research, whether sponsored by the National Institutes
of Health (NIH), foundations, or private companies. The reasons for this are
that it is easier to do and it relatively well funded (thus the “large investments”).
Many years ago, researchers, particularly those providing
primary care, distinguished between “disease-oriented evidence” (DOEs) and “patient-oriented
evidence” (POEs, or later, adding “that matters”, POEMs). The first is about
showing that a treatment improves a disease. The second is looking at what
treatments improve the life of a person. There is a big difference. A simple
example might be in looking a regimen for diabetes that minimizes the
complications from high blood sugar by keeping the average blood sugar much
lower than had previously been the goal (called “tight control”).
Disease-oriented evidence might show that using frequent insulin injections to
keep the blood sugar in the low-normal range reduces the long-term negative
effects of diabetes. A patient-oriented approach, however, looks at the overall
impact on the person, not just the disease. Does the patient find it difficult
to administer more frequent injections of insulin and check their blood sugar?
Do they spend a significant amount of time with blood sugar that is in fact too
low (after all, reducing the average increases
the probability that sometimes it will be too low), and feel fuzzy-headed and
unable to live the lives they wish to? Or feel dizzy? Or that a certain percent
actually pass out from low blood sugar? Maybe break their hips and end up in
the hospital or even dying from its complications? Even though their diabetes
is in “good” control? “The disease was
controlled but the patient died from a complication of treatment” is not a
desirable patient-oriented outcome!
The motivation for private companies, most often
pharmaceutical companies, to fund disease-oriented research is fairly obvious.
Their sole agenda is to make profit, so they are interested in supporting
research that shows that their drugs are effective for treating certain
conditions. They have a number of advantages in this arena:
·
Showing “effectiveness” requires, by FDA
criteria, only to show that a new drug or other treatment is more effective
than placebo, not than the currently available treatments;
·
Since they are paying for it, they can suppress
the publication of results that do not show their drugs in a good light;
·
They have to show only that it modifies the
disease, not that it is the best choice for any individual patient (thus it is Disease-oriented, rather than Patient-oriented);
·
In lieu of patient-centered research, they have
huge marketing budgets (far in excess of their research budgets) to advertise their
products to both providers and directly to patients once they have been
approved by the FDA.
Why NIH would mostly fund this sort of research is more
complicated. Part of it is that an entire industry has been built around doing disease-oriented
research, largely in biological science laboratories, but also in doing clinical
trials in people. Thousands of academics and the institutions at which they
work are dependent upon such funding to maintain and advance their careers and
institutions. The review committees that make recommendations to approve or
disapprove funding are “peer” committees, made up of people who do, largely,
the same kind of work. This is good because they can understand and evaluate
the science involved (a really bad
thing would be for a group of politically-appointed ideologues to make the
decisions, and this sometimes has occurred), but they are limited by their
understanding of how research is done and what its goals should be. This relates
to a second challenge – patient-oriented research is more complicated, more
difficult to do, and leads to less “clear” outcomes. Of course, it is more
relevant to patients and their providers making decisions about their care, but
it is harder to fit into a rigid research model in which all but one variable
is tightly controlled. This can lead to research that is done because it is
possible to do it, rather than because it answers the questions that we have
(see “Defining
Streetlight Research”, February 26, 2009). Most traditional NIH researchers
have no objection to patient-oriented research, but in an era of limited
funding availability might be quite concerned if funding it decreased the
amount available for the kind of work that they do.
Trying to address this, the Affordable Care Act of 2010
established the Patient-Centered Outcomes Research Institute (PCORI) to apply
the rigorous standards of Clinical Effectiveness Research (CER) to treatment of
patients, not diseases. One clear
need here is that people, particularly older people, often have more than one
disease. The “right” treatment for a patient’s cancer needs to take into
account its effect on his/her diabetes – or heart disease, hypertension,
arthritis, depression, alcoholism, glaucoma, poverty, and yes, maybe, another
cancer – in any or all combination. Because we care for the person, who may
have any or all of these conditions, primary care doctors are likely to be more
sensitive to these interactions than are physicians caring for only one of
them. It is for this reason that we have advocated for a National Center for
Primary Care to look at the comprehensive care of patients differently than the
existing disease-oriented Centers (e.g, the National Cancer Institute, the
National Center for Heart, Lung and Blood Disorders, the National Institute of
Mental Health) have.
The article in the April 18, 2012 issue of JAMA from which the opening quotation is
drawn, “Methodological
Standards and Patient-Centeredness in Comparative Effectiveness Research”,
includes the following case as an example:
“A
78-Year-Old Man with Heart Failure, Diabetes, and Renal Failure. Mr B was
admitted to his local hospital for the fourth time this year. Mr B experienced
symptoms of shortness of breath and weight gain that led him to contact his
physician, who recommended another hospitalization. He lives with his wife in a
2-story house located 30 miles from the hospital. He has recently been unable
to climb the stairs to his bedroom. Mr B requires outpatient hemodialysis 3
times per week, but missed his last dialysis treatment because he felt too
tired to go. This is his second hospital admission after missing a dialysis
appointment. After each admission, Mr B received standard discharge
instructions on how to care for himself at home. Mr B's highest priority is his
independence, including the ability to drive and to remain in his own home.”
To make appropriate decisions about Mr B’s care requires not
only considering the interplay of his several chronic diseases, but the
circumstance of, and his own preferences and goals for his life. This cannot be
done by employing solely the findings of disease-oriented research.
PCORI is not a National Institute for Primary Care, but it
may help to achieve some of the same goals. In the same issue of JAMA, Joe Selby (the director of PCORI)
and colleagues list the both the statutory criteria for PCOR-funded research:[2]
- Effect on the health of individuals
and populations
- Probability of improvability through
research
- Inclusiveness of different
populations
- Current gaps in knowledge/variation
in care
- Effect on health care system
performance
- Potential to influence decision
making
- Patient-centeredness
- Rigorous research methods
- Efficient use of research resources
and their proposed priorities for national research:
- Assessment of options for prevention,
diagnosis, and treatment
- Improving health care systems
- Dissemination and communications
research
- Addressing disparities
- Accelerating patient-centered
outcomes research and methodology
None of these are
disease specific, although unquestionably much of the research that is funded
by PCORI will look at people with specific diseases. These criteria, however, recognize
the need for treatment plans to take into account all aspects of a person, and
by extension the family and community of which they are a part. This includes addressing the disparities that exist between groups, especially poor and minority groups; that is to say, addressing issues of social determinants of health and social injustice.
Maybe we will
finally get funding for studies that provide us will more useful information
for caring for actual people.
[1]
Methodology Committee of the Patient Center Outcomes Research Institute, “MethodologicalStandards and Patient-Centeredness in Comparative Effectiveness Research”, JAMA, 2012;307(15):1636-1640. doi:
10.1001/jama.2012.466.
[2]
Selby JV, Beal AC, Frank L, “The Patient-Centered
Outcomes Research Institute (PCORI) National Priorities for Research and
Initial Research Agenda”, JAMA 2012;307(15):2583-4.
Doi: 10.1001/jama.2012.500
1 comment:
A related problem is that blood glucose is a surrogate and does not necessarily improve the outcomes we care about. Thus, rosiglitazone lowers blood sugar but increases the risk of heart attacks. In the ACCORD trial, intensive glucose control increased mortality.
Unfortunately, those articles in JAMA are behind a paywall, but the PCORI website has quite a bit of information. This page discusses what Patient-centered Outcomes Research is:
http://www.pcori.org/patient-centered-outcomes-research/
On the PCORI YouTube channel are videos from the National Patient and Stakeholder Dialogue:
http://www.youtube.com/watch?v=sKOMDFnqkoY
Post a Comment